查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1972781

貓科動物藥品市場：依治療領域、產品類型、給藥途徑及最終用戶分類－2026-2032年全球預測

Cat Medicines Market by Therapeutic Area, Product Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，貓科動物藥品市場價值將達到 166 億美元，到 2026 年將成長到 182.7 億美元，到 2032 年將達到 339.4 億美元，複合年成長率為 10.74%。

主要市場統計數據
基準年 2025 166億美元
預計年份：2026年 182.7億美元
預測年份 2032 339.4億美元
複合年成長率 (%) 10.74%

簡潔地介紹了正在重新定義整個獸醫生態系統中貓科動物治療藥物的開發、臨床預期和商業性可用性的不斷演變的促進因素。

現代貓科動物治療領域的格局正因科技進步、寵物飼主期望的改變以及新型獸醫服務模式的融合而重塑。生物製藥的創新、藥物製劑的改進以及更精準的給藥方法不斷湧現，同時，人們對動物福利、合理使用抗生素以及人與動物之間情感紐帶的關注也日益成長。精簡的供應鏈和日益複雜的監管環境也提高了產品可靠性和合規性的要求。

生物製藥、數位醫療、飼主行為、供應鏈和法規的現代化推動了貓科動物醫療保健領域的重大變革。

多項變革正在重塑貓科動物藥物的發現、研發和給藥方式。生物製藥和疫苗技術的進步加速了標靶治療和預防性產品的研發。同時，藥物科學的同步發展使得緩釋注射劑、口服和外用療法等更便於飼主使用的製劑成為可能。數位化工具、遠端醫療平台和遠端監測技術正在改變獸醫診斷和管理慢性疾病的方式，為提高用藥依從性和治療後後續觀察創造了新的途徑。

2025年美國新關稅對貓科動物治療藥物採購、生產及商業性彈性策略的影響

美國2025年實施的新關稅措施，正對貓科動物製藥業的企業採購、生產決策和成本結構產生連鎖反應。此前，這些企業受益於與跨國供應商建立的跨境供應鏈，但關稅的提高迫使它們重新評估原產地策略，盡可能優先考慮本地生產，並修訂供應商合約以降低成本波動風險。為此，企業正加速推動近岸外包和供應商多元化，以減少對單一貿易路線的依賴。

根據治療領域、產品類型、給藥途徑和最終用戶群體，分析貓科動物治療的商業性和臨床意義。

對治療領域的細分檢驗揭示了每個類別獨特的創新和商業化路徑，包括麻醉劑、抗感染藥、抗發炎藥、內分泌治療藥物、驅蟲藥和疫苗。在麻醉劑領域，全身麻醉和局部麻醉的差異影響製劑的選擇和手術全期通訊協定；局部麻醉劑適用於門診病人，而全身麻醉劑則在複雜的手術中發揮其特殊作用。抗感染劑分為注射用抗生素和口服抗生素，影響處方模式、合理用藥方案、病人用藥責任。抗發炎藥物分為非類固醇消炎劑（NSAIDs）和類固醇，每種藥物都有其獨特的安全性特徵和監測要求，這些因素決定了產品標籤和獸醫指導政策。內分泌治療藥物分為胰島素製劑和甲狀腺製劑，需要不同的給藥系統和藥物支持，尤其是在慢性病治療中。驅蟲藥依其劑型分為注射劑、口服劑和外用劑，這導致患者的購買行為和用藥依從性有差異。疫苗則分為去活化疫苗和活病毒疫苗，這導致其冷藏管理、儲存期限和接種程序有差異。

美洲、歐洲、中東和非洲以及亞太地區的區域監管、分銷和需求趨勢及其對商業策略的影響。

區域趨勢對美洲、歐洲、中東、非洲和亞太地區的監管、分銷模式和臨床實踐標準有顯著影響。在美洲，完善的獸醫網路、寵物飼主較高的消費能力以及有利於多通路策略的複雜經銷夥伴塑造了市場環境。企業通常優先考慮遵守國家監管機構的規定以及物流基礎設施的建設，以確保產品品質。在歐洲、中東和非洲，分散的管理體制和多樣化的臨床實踐標準要求企業採取個人化的市場准入策略。尤其需要關注歐洲內部的監管協調工作以及中東和非洲特定市場面臨的物流挑戰。在亞太地區，快速的都市化、可支配收入的成長以及伴侶動物服務的擴張正在加速對先進治療藥物的需求，但各地區在報銷制度、許可途徑和低溫運輸能力方面存在差異。

競爭與夥伴關係的動態如何影響貓科動物治療整個價值鏈的創新、生產柔軟性和分銷效率。

貓科動物治療領域的競爭格局呈現出多元化的特點，既有成熟的動物用藥品公司，也有專注生物製藥研發的專業公司，還有靈活的契約製造，以及新興的數位醫療領域的參與企業。成熟公司利用其規模和全球分銷網路，維持豐富的產品系列和完善的藥物監測系統。同時，專業公司正致力於研發差異化技術，例如新型疫苗平台、緩釋注射劑和標靶內分泌療法。契約製造組織（CMO）和製劑專家正日益成為重要的合作夥伴，他們能夠柔軟性進行無菌和非無菌生產，並加快新產品進入臨床試驗階段的速度。

產業領導者應採取具有重大影響力的策略行動和營運重點，以增強韌性、實現商業化並提供長期治療價值。

產業領導者應優先採取一系列營運和策略行動，以在持續的市場動盪中創造價值。首先，將研發投資集中在臨床需求與可行差異化結合的高價值治療領域，將有助於提高研發效率和商業性價值。其次，透過投資地理多元化、檢驗的二級供應商以及契約製造，降低供應鏈風險，進而減輕關稅和物流衝擊帶來的影響。第三，透過投資開發更方便患者使用的劑型和給藥工具，提高產品的易用性，可以顯著提高患者的用藥依從性和品牌偏好。

高度透明、以從業者觀點的研究方法，將二手監管和科學記錄與一手訪談以及交叉檢驗的交易和安全數據相結合。

本分析所依據的研究結合了結構化的二手資料研究、一手定性訪談以及多方資訊來源三角檢驗，從而對貓科動物治療藥物的市場趨勢進行了全面而深入的分析。二級資訊來源包括監管文件、臨床試驗註冊資訊、專利文件、生產和分銷指南以及公開的產品標籤和安全資訊。研究人員對這些資料進行了系統性的審查，以識別技術趨勢、監管趨勢和產品層面的差異化因素。

對科學創新、供應鏈韌性和商業性可行性之間的相互作用進行全面分析。這些因素將決定貓科動物治療領域的長期成功。

分析表明，貓科動物治療領域正處於轉折點。科學進步、終端用戶期望的改變以及政策的調整相互交織，既帶來了機遇，也帶來了挑戰。治療差異化越來越依賴製劑技術、生物製藥和疫苗平台的創新性，以及能否根據飼主的日常習慣和獸醫的工作流程提供治療。貿易政策和供應鏈的實際情況正從後勤部門考量轉變為影響採購、定價和生產力計畫的核心策略工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：貓科動物藥品市場：依治療領域分類

  • 麻醉劑
    • 一般的
    • 局部的
  • 抗感染藥物
    • 注射用抗生素
    • 口服抗生素
  • 抗發炎藥
    • 非類固醇消炎劑（NSAIDs）
    • 類固醇
  • 內分泌系統
    • 胰島素
    • 甲狀腺
  • 殺蟲劑
    • 注射藥物
    • 口服
    • 外用藥物
  • 疫苗
    • 失活
    • 活病毒疫苗

第9章：貓用藥品市場：依產品類型分類

  • 注射藥物
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 液體
    • 口服液體藥物
    • 懸浮液
    • 糖漿
  • 固態劑型
    • 膠囊
    • 粉末
    • 藥片
  • 外部產品
    • 軟膏
    • 洗髮精
    • 點塗治療藥物

第10章：貓用藥品市場：依給藥途徑分類

  • 口服
    • 口服液體藥物
    • 口服固態劑型
  • 腸外
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 外用藥物
    • 局部應用
    • 經皮吸收

第11章：貓用藥品市場：依最終用戶分類

  • 寵物飼主
  • 獸醫專家
    • 醫院和診所
    • 私人執業獸醫

第12章：貓用藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：貓用藥品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：貓用藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國貓科動物藥品市場

第16章：中國貓藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bimeda, Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Heska Corporation
  • Hester Biosciences Ltd.
  • IDEXX Laboratories Inc.
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-9A6A6F297DE3

The Cat Medicines Market was valued at USD 16.60 billion in 2025 and is projected to grow to USD 18.27 billion in 2026, with a CAGR of 10.74%, reaching USD 33.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.60 billion
Estimated Year [2026] USD 18.27 billion
Forecast Year [2032] USD 33.94 billion
CAGR (%) 10.74%

A concise primer on the shifting drivers redefining feline therapeutic development, clinical expectations, and commercial delivery across the veterinary ecosystem

The contemporary landscape of feline therapeutics is being reshaped by converging scientific advances, evolving pet owner expectations, and new models of veterinary care delivery. Biological innovations, refined formulations, and more precise dosing modalities are emerging alongside heightened attention to animal welfare, antimicrobial stewardship, and the human-animal bond. At the same time, supply chain rationalization and a more complex regulatory environment are raising the bar for product reliability and compliance.

Transitioning from conventional product development paradigms, stakeholders across the value chain-from pharmaceutical developers and contract manufacturers to distributors and veterinary practitioners-are adapting to a faster cadence of innovation and a demand for differentiated value. This introduction frames the broader market drivers and the strategic tensions that follow: balancing efficacy and safety, meeting diverse end-user needs, and aligning commercial models with shifting clinical and consumer behaviors. These dynamics set the stage for deeper analysis across therapeutic categories, product formats, distribution channels, and regional nuances that follow in subsequent sections.

Key transformative shifts in feline medicine driven by biologics, digital health, owner behavior, and supply chain and regulatory modernization

Several transformative shifts are redefining how feline medicines are discovered, developed, and delivered. Advances in biologics and vaccine technologies have accelerated the development of targeted therapeutics and preventative products, while parallel progress in formulation science has enabled extended-release injectables and owner-friendly oral or topical treatments. Digital tools, telehealth platforms, and remote monitoring technologies are changing how veterinarians diagnose and manage chronic conditions, creating new touchpoints for adherence and post-treatment surveillance.

Behavioral and demographic trends among pet owners are also significant: greater willingness to invest in advanced care, demand for convenience in dosing and administration, and stronger interest in wellbeing and preventative medicine. Supply chain modernization and regulatory harmonization efforts are encouraging higher manufacturing quality and transparency, but they also introduce complexity that companies must manage. Taken together, these shifts are prompting incumbents and new entrants to re-evaluate R&D priorities, distribution partnerships, and commercial models to remain responsive to a rapidly evolving ecosystem.

How new United States tariff measures are reshaping sourcing, manufacturing, and commercial resilience strategies for feline therapeutics throughout 2025

The introduction of new tariff measures in the United States during 2025 is creating a ripple effect across sourcing, manufacturing decisions, and cost structures for companies operating in the feline medicines space. Where previously multinational suppliers benefited from established cross-border supply chains, rising duties are prompting firms to re-examine origin-of-goods strategies, prioritize local production where feasible, and reassess supplier contracts to mitigate cost volatility. As firms respond, there is an observable acceleration in nearshoring and diversification of supplier bases to limit exposure to a single trade corridor.

Pharmaceutical-grade raw materials, specialized excipients, and certain finished formulations that move across borders are particularly sensitive to tariff-driven cost pressures. In response, organizations are adjusting procurement protocols, expanding long-term supplier agreements with price corridors, and investing in manufacturing resilience such as dual sourcing and flexible production lines. These strategic shifts are also influencing pricing negotiations with distributors and veterinary practices, procurement cycles within veterinary institutions, and investment considerations for manufacturing capacity expansions. Regulatory compliance and customs planning have become more central to commercial strategies, and companies that integrate trade policy analysis with operational planning are better positioned to sustain product availability and margin integrity.

Strategic commercial and clinical implications derived from therapeutic area, product type, administration route, and end user segmentation for feline therapeutics

Examining therapeutic area segmentation reveals distinct innovation and commercialization pathways across categories such as anesthetics, anti-infectives, anti-inflammatories, endocrine therapies, parasiticides, and vaccines. Within anesthetics, the differentiation between general and local approaches affects formulation choices and perioperative protocols, with local agents enabling outpatient-friendly procedures and general agents retaining a specialized role in complex surgeries. Anti-infectives are bifurcated between injectable antibiotics and oral antibiotics, which influence prescribing patterns, stewardship programs, and client administration responsibilities. Anti-inflammatories split into NSAIDs and steroids, each presenting unique safety and monitoring profiles that inform labeling and veterinarian guidance. Endocrine therapies divided into insulin and thyroid products require divergent delivery systems and adherence support, especially for chronic care pathways. Parasiticides differentiated by injectable, oral, and topical modalities create varied purchase and compliance behaviors, while vaccines categorized as inactivated or live shape refrigeration logistics, shelf life, and vaccination schedules.

Looking at product type segmentation, injectable products-further distinguished by intramuscular, intravenous, and subcutaneous routes-demand different clinical settings and training, affecting where and how they are administered. Liquid dosage forms encompassing oral solutions, suspensions, and syrups are often favored for ease of use in certain populations, while solid dosage forms such as capsules, powders, and tablets support stability and precise dosing. Topical products including ointments, shampoos, and spot-on treatments align closely with owner-led administration and retail distribution channels. Route of administration segmentation highlights oral, parenteral, and topical pathways, each with subcategories influencing adherence, pharmacokinetics, and product design such as local topical versus transdermal delivery or liquid oral versus solid oral formulations. Finally, end-user segmentation differentiates between pet owners and veterinary professionals, with the latter further split into hospital clinics and private practices; this distinction underscores divergent purchasing behaviors, clinical competencies, and communication needs that influence product positioning, educational initiatives, and support services.

Regional regulatory, distribution, and demand dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific and their implications for commercial strategy

Regional dynamics exert a powerful influence on regulation, distribution models, and clinical practice standards across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, the landscape is shaped by sophisticated veterinary networks, strong pet owner spending, and complex distribution partnerships that favor multi-channel strategies; companies often prioritize compliance with national regulatory authorities and logistics infrastructure to maintain product integrity. In Europe, Middle East & Africa, fragmented regulatory regimes and diverse clinical practice norms require tailored market entry approaches, with particular attention to harmonization efforts within European jurisdictions and logistics challenges in certain Middle Eastern and African markets. In Asia-Pacific, rapid urbanization, rising disposable income, and growing penetration of companion animal services are accelerating demand for advanced therapeutics, but the region also presents heterogeneity in reimbursement, licensing pathways, and cold-chain capabilities.

These regional differences have practical implications for portfolio prioritization, clinical trial design, and distribution networks. Supply chain resilience measures, such as regional production hubs and localized packaging or labelling, are increasingly important to meet regulatory and logistical demands. Additionally, educational programs and marketing must be regionally calibrated to account for local clinical protocols, cultural attitudes toward pets, and the relative maturity of veterinary services. Companies that align product design, compliance strategies, and go-to-market models with these regional realities can more effectively convert global R&D into sustainable commercial performance across diverse territories.

Competitive landscape and partnership dynamics shaping innovation, manufacturing flexibility, and distribution effectiveness across the feline therapeutic value chain

The competitive landscape in feline therapeutics is characterized by a mix of long-established animal health companies, specialist biologics developers, agile contract manufacturers, and an expanding cohort of digital health entrants. Incumbent firms continue to leverage scale and global distribution reach to support wide product portfolios and robust pharmacovigilance systems. Meanwhile, specialist players are advancing differentiated technologies such as novel vaccine platforms, extended-release injectables, and targeted endocrine therapies. Contract manufacturing organizations and formulation specialists are increasingly important partners, enabling faster time-to-clinic for novel products while offering manufacturing flexibility across sterile and non-sterile processes.

Distribution partners, including veterinary wholesalers and retail chains, play a critical role in maintaining product availability and supporting education at the point of care. Digital-first companies focused on telehealth, treatment adherence platforms, and remote monitoring are reshaping how products are prescribed and supported post-sale. Across this landscape, winners are those that integrate clinical evidence generation with commercialization capabilities, maintain rigorous quality controls, and invest in customer-centric services such as practitioner training, owner adherence supports, and transparent supply chain practices. Strategic alliances, licensing deals, and targeted acquisitions remain common mechanisms for accessing complementary capabilities and accelerating pipeline maturation.

High-impact strategic actions and operational priorities that industry leaders should adopt to strengthen resilience, commercialization, and long-term therapeutic value delivery

Industry leaders should prioritize a set of operational and strategic actions to capture value amid ongoing disruption. First, aligning R&D investment with high-value therapeutic niches-where clinical need and feasible differentiation intersect-will improve development efficiency and commercial relevance. Second, de-risking supply chains through geographic diversification, validated secondary suppliers, and investments in contract manufacturing capacity will reduce exposure to tariff and logistics shocks. Third, enhancing product usability by investing in owner-friendly dose forms and administration tools can materially improve adherence and brand preference.

In parallel, companies should formalize digital engagement strategies that combine practitioner education, telemedicine integrations, and adherence monitoring to support long-term therapeutic outcomes. Regulatory and quality teams must be integrated early into product development to streamline approvals, labeling, and pharmacovigilance. Finally, commercial models should be tailored to end-user segments: sophisticated, evidence-focused engagement with veterinary professionals and convenience-plus-education approaches for owners. Executing these recommendations requires cross-functional governance, outcome-oriented KPIs, and a willingness to pilot novel distribution and service models that can scale rapidly when validated.

A transparent and practitioner-informed research approach combining secondary regulatory and scientific records with primary interviews and cross-validated trade and safety data

The research behind this analysis combines structured secondary research, primary qualitative interviews, and triangulation across multiple information sources to produce a robust view of the feline therapeutics landscape. Secondary inputs include regulatory filings, clinical trial registries, patent literature, manufacturing and distribution guidelines, and publicly available product labeling and safety communications. These materials were systematically reviewed to identify technological trends, regulatory shifts, and product-level differentiation.

Primary research consisted of in-depth interviews with veterinary clinicians across hospital clinics and private practices, procurement managers at distribution partners, R&D and manufacturing leads at pharmaceutical and contract organizations, and specialist veterinarians focusing on endocrinology, parasitology, and infectious disease. Where appropriate, findings were validated through cross-comparison with trade data, customs filings, and pharmacovigilance reports to ensure consistency and identify emerging patterns. Analytical frameworks applied include value-chain mapping, risk exposure analysis for supply and tariff impacts, and segmentation-driven persona development for end users. Together, these methodological steps support a defensible, practitioner-informed account of current dynamics and strategic implications.

Concluding synthesis on the interplay between scientific innovation, supply chain resilience, and commercial execution that will determine long-term success in feline therapeutics

This analysis demonstrates that the feline therapeutics sector is at an inflection point where scientific momentum, changing end-user expectations, and policy shifts intersect to create both opportunity and complexity. Therapeutic differentiation increasingly depends on formulation ingenuity, biologic and vaccine platforms, and the ability to deliver treatments in ways that align with owner routines and veterinary workflows. Trade policy and supply chain realities have moved from back-office considerations to central strategic levers that influence sourcing, pricing, and capacity planning.

Organizations that succeed will be those that integrate clinical evidence generation with flexible manufacturing and distribution strategies, embrace digital channels for practitioner and owner engagement, and proactively mitigate trade and regulatory risks. Moving forward, cross-functional collaboration-spanning R&D, regulatory, manufacturing, and commercial teams-will be essential to convert innovation into durable clinical impact and sustainable business performance. The priorities outlined here provide a blueprint for executives seeking to navigate the near-term disruptions while positioning for long-term growth and resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cat Medicines Market, by Therapeutic Area

  • 8.1. Anesthetics
    • 8.1.1. General
    • 8.1.2. Local
  • 8.2. Anti-Infectives
    • 8.2.1. Injectable Antibiotics
    • 8.2.2. Oral Antibiotics
  • 8.3. Anti-Inflammatories
    • 8.3.1. NSAIDs
    • 8.3.2. Steroids
  • 8.4. Endocrine
    • 8.4.1. Insulin
    • 8.4.2. Thyroid
  • 8.5. Parasiticides
    • 8.5.1. Injectable
    • 8.5.2. Oral
    • 8.5.3. Topical
  • 8.6. Vaccines
    • 8.6.1. Inactivated
    • 8.6.2. Live

9. Cat Medicines Market, by Product Type

  • 9.1. Injectable Products
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Liquid Dosage Forms
    • 9.2.1. Oral Solutions
    • 9.2.2. Suspensions
    • 9.2.3. Syrups
  • 9.3. Solid Dosage Forms
    • 9.3.1. Capsules
    • 9.3.2. Powders
    • 9.3.3. Tablets
  • 9.4. Topical Products
    • 9.4.1. Ointments
    • 9.4.2. Shampoos
    • 9.4.3. Spot-On Treatments

10. Cat Medicines Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Liquid Oral
    • 10.1.2. Solid Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Local Topical
    • 10.3.2. Transdermal

11. Cat Medicines Market, by End User

  • 11.1. Pet Owners
  • 11.2. Veterinary Professionals
    • 11.2.1. Hospital Clinics
    • 11.2.2. Private Practices

12. Cat Medicines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cat Medicines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cat Medicines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cat Medicines Market

16. China Cat Medicines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bimeda, Inc.
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Ceva Sante Animale S.A.
  • 17.8. Dechra Pharmaceuticals PLC
  • 17.9. Elanco Animal Health Incorporated
  • 17.10. Heska Corporation
  • 17.11. Hester Biosciences Ltd.
  • 17.12. IDEXX Laboratories Inc.
  • 17.13. Merck & Co., Inc.
  • 17.14. Phibro Animal Health Corporation
  • 17.15. Vetoquinol S.A.
  • 17.16. Virbac S.A.
  • 17.17. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAT MEDICINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAT MEDICINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAT MEDICINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAT MEDICINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAT MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAT MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAT MEDICINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAT MEDICINES MARKET SIZE, BY GENERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAT MEDICINES MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAT MEDICINES MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAT MEDICINES MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAT MEDICINES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAT MEDICINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAT MEDICINES MARKET SIZE, BY LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAT MEDICINES MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CAT MEDICINES MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CAT MEDICINES MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CAT MEDICINES MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CAT MEDICINES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CAT MEDICINES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CAT MEDICINES MARKET SIZE, BY SHAMPOOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CAT MEDICINES MARKET SIZE, BY SPOT-ON TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CAT MEDICINES MARKET SIZE, BY LIQUID ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CAT MEDICINES MARKET SIZE, BY SOLID ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CAT MEDICINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CAT MEDICINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAT MEDICINES MARKET SIZE, BY LOCAL TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CAT MEDICINES MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CAT MEDICINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CAT MEDICINES MARKET SIZE, BY HOSPITAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CAT MEDICINES MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CAT MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CAT MEDICINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 320. GLOBAL CAT MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. ASEAN CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. ASEAN CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 323. ASEAN CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 324. ASEAN CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 325. ASEAN CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CAT MEDICINES MARKET SIZE, BY TOPICAL PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CAT MEDICINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CAT MEDICINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CAT MEDICINES MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CAT MEDICINES MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CAT MEDICINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CAT MEDICINES MARKET SIZE, BY VETERINARY PROFESSIONALS, 2018-2032 (USD MILLION)
  • TABLE 340. GCC CAT MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 341. GCC CAT MEDICINES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 342. GCC CAT MEDICINES MARKET SIZE, BY ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 343. GCC CAT MEDICINES MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 344. GCC CAT MEDICINES MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 345. GCC CAT MEDICINES MARKET SIZE, BY ENDOCRINE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC CAT MEDICINES MARKET SIZE, BY PARASITICIDES, 2018-2032 (USD MILLION)
  • TABLE 347. GCC CAT MEDICINES MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 348. GCC CAT MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. GCC CAT MEDICINES MARKET SIZE, BY INJECTABLE PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 350. GCC CAT MEDICINES MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 351. GCC CAT MEDICINES MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILL